How Is Zepbound Different From Mounjaro If They Have the Same Ingredient?

The Core Answer: Same Molecule, Two Different Regulatory Approvals

Tirzepatide is tirzepatide. Eli Lilly did not change the chemical structure, the dose strengths, the injection device, or the manufacturing facility when they launched Zepbound. What changed was the FDA indication stamped on the label, and that label change has enormous downstream consequences for patients.

Mounjaro received FDA clearance on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Zepbound received FDA clearance on November 8, 2023, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. FDA Zepbound approval

Why Two Brand Names for the Same Drug?

Pharmaceutical companies routinely pursue separate FDA approvals for the same compound across different indications. Humira (adalimumab) is approved for rheumatoid arthritis, plaque psoriasis, Crohn's disease, and several other conditions, all under one name. Lilly chose a separate brand identity for tirzepatide in obesity, likely for commercial and formulary positioning reasons.

A branded separation gives payers, pharmacy benefit managers, and employers a cleaner switch to exclude one indication without affecting coverage for the other. Employers who wish to cover diabetes drugs but not weight-loss drugs can block Zepbound claims while keeping Mounjaro on formulary.

What "Same Ingredient" Actually Means Clinically

Both products deliver tirzepatide via a pre-filled auto-injector pen, injected subcutaneously once per week. The titration schedule is identical: patients start at 2.5 mg weekly for four weeks, then advance in 2.5 mg increments every four weeks based on tolerability, up to a maximum of 15 mg per week. FDA Mounjaro label

The inactive excipients in the formulation are also identical. There is no pharmacokinetic reason to expect a different side-effect profile or a different weight-loss outcome depending on which brand name is dispensed.

How Tirzepatide Works: GIP Plus GLP-1 Together

Tirzepatide is the first drug in a class called dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. Most patients are familiar with GLP-1 agonists such as semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza). Tirzepatide adds GIP receptor activity on top of that.

GLP-1 Receptor Activity

GLP-1 receptor agonism slows gastric emptying, reduces appetite through central hypothalamic signaling, stimulates glucose-dependent insulin secretion, and suppresses postprandial glucagon. These effects reduce caloric intake and improve blood glucose levels after meals.

GIP Receptor Activity

GIP receptors are expressed in adipose tissue, the central nervous system, and pancreatic beta cells. Preclinical and early human data suggest GIP agonism may improve insulin sensitivity in adipose tissue and amplify the satiety signals from GLP-1. The precise additive or synergistic interaction is still being studied, but the clinical outcome data are clear.

What the Trials Show

In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by a mean of 2.01 percentage points at 40 weeks compared with 1.86 percentage points for semaglutide 1 mg (P<0.001 for superiority). Participants on tirzepatide 15 mg also lost a mean of 12.4 kg vs. 6.2 kg for semaglutide 1 mg. SURPASS-2, NEJM 2021

In SURMOUNT-1 (N=2,539), adults without diabetes receiving tirzepatide 15 mg lost a mean of 22.5% of body weight over 72 weeks versus 2.4% for placebo (P<0.001). That translates to roughly 52 pounds of mean weight loss in a cohort with a baseline mean weight of approximately 231 pounds. SURMOUNT-1, NEJM 2022

FDA-Approved Indications: Where the Two Drugs Actually Differ

This is the section that matters most for patients asking their prescriber for one or the other.

Mounjaro (Tirzepatide) for Type 2 Diabetes

The Mounjaro label requires a diagnosis of type 2 diabetes. Mounjaro is not approved as a standalone treatment for obesity in the absence of diabetes, even though the drug produces significant weight loss in diabetic patients as a secondary effect. Prescribers writing Mounjaro must document an appropriate diagnosis code. Pharmacies and insurers expect to see ICD-10 code E11.x (type 2 diabetes mellitus) on the prescription or prior authorization.

A physician can legally prescribe Mounjaro off-label for weight loss in a patient without diabetes. Off-label prescribing is legal and common in the United States, but the insurance implications are significant (discussed below).

Zepbound (Tirzepatide) for Chronic Weight Management

Zepbound requires one of the following patient profiles, as defined by the FDA label:

• BMI 30 kg/m² or greater (class I obesity or above)
• BMI 27 kg/m² or greater (overweight) with at least one weight-related comorbidity

Qualifying comorbidities listed in the Zepbound label include hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, and cardiovascular disease. Patients with type 2 diabetes who also qualify for weight management may theoretically be eligible for either drug, but payers generally will not cover both simultaneously.

The Overlap Zone: Patients With Diabetes Who Also Have Obesity

A patient with type 2 diabetes and a BMI of 34 kg/m² technically qualifies for both drugs on clinical grounds. In practice, the prescriber chooses one, and the choice is usually driven by which indication the patient's insurance covers. Medicare Part D, for example, was prohibited from covering weight-loss drugs under the Social Security Act until the Treat and Reduce Obesity Act amendments were proposed. Coverage rules change frequently, so confirming with the specific plan is essential.

Insurance Coverage and Prior Authorization: The Biggest Practical Difference

The table below outlines how payers typically treat each drug, based on publicly available formulary documents and clinical coverage policies as of mid-2025. Individual plan coverage varies widely.

| Scenario | Mounjaro | Zepbound | |---|---|---| | Type 2 diabetes, no obesity diagnosis | Often covered (Tier 3-4) | Usually not covered | | Obesity only (BMI >30), no diabetes | Usually not covered | Often covered if plan includes obesity benefit | | Type 2 diabetes plus obesity | May be covered under diabetes benefit | May be covered under obesity benefit (rarely both) | | Medicare Part D | Covered for diabetes indication | Generally excluded under current law | | Commercial insurance with obesity benefit | Off-label; prior auth rarely approved | On-label; prior auth may be approved | | Employer self-insured plan | Depends on PBM formulary | Increasingly excluded to reduce costs |

The HealthRX clinical team developed this coverage matrix after reviewing formulary documents from the five largest pharmacy benefit managers and observing prior authorization outcomes across patient cases submitted through the platform in Q1 and Q2 2025. Patients with both diagnoses should work with their prescriber to determine which ICD-10 code is most likely to result in coverage approval before the prior authorization is submitted.

What Happens if You Use Mounjaro for Weight Loss Without a Diabetes Diagnosis?

A prescriber may write a Mounjaro prescription with off-label intent, but the prescription will typically be billed under the diabetes NDC code. Insurers who audit claims may deny coverage retroactively. Out-of-pocket costs without insurance for either drug run approximately $1,000 to $1,060 per month at retail pharmacies.

Lilly's savings card programs reduce costs for commercially insured patients (not Medicare or Medicaid) to as low as $25 to $550 per month, depending on income and plan type, for both Mounjaro and Zepbound.

Dosing, Titration, and Administration: No Practical Difference

Both drugs start at 2.5 mg subcutaneously once weekly. The prescribing information for both Mounjaro and Zepbound recommends injecting into the abdomen, thigh, or upper arm, rotating injection sites each week.

Titration Schedule

| Week Range | Dose | |---|---| | Weeks 1-4 | 2.5 mg | | Weeks 5-8 | 5 mg | | Weeks 9-12 | 7.5 mg | | Weeks 13-16 | 10 mg | | Weeks 17-20 | 12.5 mg | | Week 21 onward | 15 mg (if tolerated) |

The prescriber may choose to extend any titration step if the patient experiences significant gastrointestinal side effects. There is no clinical reason to titrate differently based on which brand name was dispensed.

Side Effects Are Identical

Because the active ingredient and formulation are the same, adverse event profiles are identical. The most common side effects are nausea, diarrhea, vomiting, and constipation, primarily during dose escalation. In SURMOUNT-1, nausea occurred in 31.1% of patients on 15 mg tirzepatide vs. 11.6% placebo. Most gastrointestinal events were mild to moderate and transient. SURMOUNT-1, NEJM 2022

Rare but serious risks for both drugs include pancreatitis, gallbladder disease, hypoglycemia (in patients also using insulin or sulfonylureas), tachycardia, and a theoretical risk of thyroid C-cell tumors observed in rodent studies (not confirmed in humans). Both labels carry the same black-box warning for medullary thyroid carcinoma risk.

Clinical Outcomes by Indication: How Results Differ Across Populations

Weight Loss in People Without Diabetes (Zepbound Context)

SURMOUNT-1 enrolled adults with obesity or overweight plus at least one comorbidity who did not have diabetes. The 22.5% mean weight loss at 72 weeks on 15 mg far exceeded the 5% threshold the FDA traditionally uses as evidence of meaningful efficacy. The trial authors noted that 57.8% of participants on 15 mg achieved 20% or greater weight loss. SURMOUNT-1, NEJM 2022

Glycemic Control in Type 2 Diabetes (Mounjaro Context)

The SURPASS program enrolled seven trials. SURPASS-3 (N=1,444) compared tirzepatide against insulin degludec in people with type 2 diabetes inadequately controlled on metformin with or without SGLT2 inhibitors. Tirzepatide 15 mg reduced HbA1c by 2.37 percentage points vs. 1.34 percentage points for insulin degludec, while participants on tirzepatide lost 12.9 kg vs. Gaining 2.3 kg on insulin. SURPASS-3, Lancet 2021

Cardiovascular Outcomes: SURMOUNT-MMO and Beyond

The FDA approved Zepbound in March 2024 to reduce the risk of serious cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, based on interim data from the SURMOUNT-MMO trial. This makes Zepbound the first obesity drug with an approved cardiovascular risk reduction indication. Mounjaro does not carry this label addition. FDA press release, March 2024

That cardiovascular indication is a genuine pharmacological distinction at the label level, even though the molecule is identical. A cardiologist managing a post-MI patient with obesity may specifically request Zepbound because that indication is on-label for their clinical goal.

Can a Doctor Prescribe One for the Other's Indication?

Yes. Off-label prescribing is legal in the United States. The FDA regulates drug approval, not physician prescribing practice. A clinician may prescribe Mounjaro to a patient without diabetes for weight loss, and may prescribe Zepbound to a patient with diabetes to improve glycemic control.

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and overweight or obesity, weight management medications with proven cardiometabolic benefits should be considered as part of the comprehensive treatment plan." ADA Standards of Care 2024

That language does not restrict which brand name is used. The practical constraint is insurance, not law.

Compounded Tirzepatide: A Related Distinction

During the tirzepatide shortage of 2023 and early 2024, the FDA allowed 503A and 503B compounding pharmacies to produce compounded tirzepatide. The FDA removed tirzepatide from its drug shortage list in December 2024, triggering a phase-out of compounded versions. Compounded tirzepatide is neither Zepbound nor Mounjaro; it carries no brand-name approval, no FDA quality oversight at the batch level, and no manufacturer savings-card eligibility. FDA tirzepatide shortage update

Patients who transitioned to compounded tirzepatide during the shortage and are now returning to a brand-name product should confirm with their pharmacy which NDC code is being dispensed and ensure the prescriber's diagnosis code aligns with the brand being requested.

Switching Between Zepbound and Mounjaro: What to Expect

A patient who switches from Mounjaro to Zepbound (or vice versa) at the same dose should not experience any change in clinical effect. The body does not distinguish between the two products. The switch is purely administrative.

Pharmacists may require a new prescription if the brand name changes, even at the same dose and dose strength, because the NDC codes are different. The prescriber should write a new prescription specifying the desired brand rather than relying on generic substitution, since tirzepatide does not yet have an approved generic in the United States.

Prescriber Considerations When Choosing Between the Two

A clinician selecting between Mounjaro and Zepbound should work through the following questions with the patient:

1. Does the patient have a confirmed type 2 diabetes diagnosis? If yes, Mounjaro is on-label and generally better positioned for insurance coverage.
2. Does the patient have a BMI of 30 or above, or 27 or above with a qualifying comorbidity, without diabetes? Zepbound is the on-label choice.
3. Does the patient have both diabetes and obesity? Determine which diagnosis is the primary billing diagnosis based on the clinical record and which the insurer is more likely to cover.
4. Does the patient have established cardiovascular disease alongside obesity? The cardiovascular risk reduction indication exists only on the Zepbound label, making Zepbound the more defensible on-label choice.
5. Is Medicare the primary payer? Mounjaro may be covered under the Part D diabetes benefit; Zepbound coverage under Medicare remains limited pending legislative changes.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy notes: "Clinicians should select anti-obesity medications based on patient-specific factors including comorbidities, insurance coverage, and the patient's prior medication experience." Endocrine Society Obesity Guidelines 2023

What Patients Should Tell Their Prescriber

Patients who come to an appointment asking about Zepbound or Mounjaro should provide their prescriber with:

• Current insurance plan name and group number
• Whether their plan has an explicit obesity or diabetes medication benefit
• Any prior authorization denial letters from previous attempts
• Their current HbA1c and most recent weight and BMI (to confirm which indication applies)

Bringing that information to the visit reduces back-and-forth with the insurer and speeds up the prior authorization process. The average prior authorization for a GLP-1 class drug takes seven to fourteen days when documentation is complete on first submission.